secwatch.observer — SEC 8-K summary
======================================

Issuer:     BECTON DICKINSON & CO (BDX)
CIK:        0000010795
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0000010795-25-000019
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BD beats Q1 estimates, announces plan to separate Biosciences and Diagnostic Solutions
--------------------------------------------------------------------------------

- Q1 revenue $5.2B (+9.8% reported, +3.9% organic); adj. EPS $3.43 (+28.0% YoY); GAAP EPS $1.04.
- Company raised FY25 adjusted diluted EPS guidance at midpoint; completed $750M share repurchase.
- BD board authorized separation of Biosciences and Diagnostic Solutions; target completion in fiscal 2026.
- New BD (post-separation) expected FY24 revenue ~$17.8B; separated business ~$3.4B with ~30% adj. EBITDA margins.
- Investor Day (Feb 26, 2025) postponed; company to provide update closer to separation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10795/000001079525000019/0000010795-25-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10795/000001079525000019/bdx-20250205.htm
  HTML page:      https://secwatch.observer/filing/0000010795-25-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer